Xin Lang Cai Jing·2025-12-19 16:42Core Viewpoint - The company intends to acquire Amicus Therapeutics for approximately $4.8 billion to expand its presence in the rare metabolic disease sector [1][3]. Group 1: Acquisition Details - The acquisition price is set at $14.50 per share, representing a 33.1% premium over Amicus's latest closing price [1][3]. - Following the announcement, Amicus's stock surged by 30%, while the acquiring company's stock rose nearly 5% in pre-market trading [1][3]. - The deal will enhance the company's product portfolio by adding several approved treatments for genetic diseases, including Galafold for Fabry disease and a combination therapy for Pompe disease [1][3]. Group 2: Financial Aspects - The company plans to finance the acquisition through existing cash reserves and approximately $3.7 billion in non-convertible debt [1][3]. - As of September 30, the company's total cash and investments amount to about $2 billion [2][4]. - The acquisition is expected to close in the second quarter of 2026 and will immediately contribute to revenue growth [2][4]. - The company anticipates that the acquisition will enhance adjusted profits within the first 12 months post-transaction and significantly boost earnings starting in 2027 [5].